Press releases
Browse LEO Pharma’s global press releases intended for media.
Press releases issued by our local operating companies can be viewed on our market websites.
-
LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab in children with moderate-to-severe atopic dermatitis
LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab in children with moderate-to-severe atopic dermatitis BALLERUP, Denmark, July 9, 2026 —LEO Pharma…
-
LEO Pharma to showcase new data highlighting the burden and unmet needs in Chronic Hand Eczema at ESCD 2026 in Copenhagen
LEO Pharma to showcase new data highlighting the burden and unmet needs in Chronic Hand Eczema at ESCD 2026 in Copenhagen BALLERUP, Denmark, June 25, 2026 — LEO Pharma…
-
LEO Pharma’s net-zero and emissions reduction targets validated by SBTi
LEO Pharma’s net-zero and emissions reduction targets validated by SBTi BALLERUP, June 8 2026 – LEO Pharma today announced that its climate targets, including its ambition to achieve net-zero…
-
LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipeline
LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipeline Ballerup, Denmark, 5 May, 2026 – In Q1 2026, LEO Pharma delivered robust revenue…
-
LEO Pharma bolsters rare skin disease focus through acquisition of Replay gene therapy platform
LEO Pharma bolsters rare skin disease focus through acquisition of Replay gene therapy platform Ballerup, Denmark, April 30, 2026 – LEO Pharma, a global leader in medical dermatology delivering…
-
LEO Pharma to nominate Kasper Fangel as new board member and Audit Committee Chair
LEO Pharma to nominate Kasper Fangel as new board member and Audit Committee Chair Ballerup, Denmark, February 23, 2026 – LEO Pharma today announced that Kasper Fangel, CEO of…
-
LEO Pharma delivers 10% revenue growth in 2025 and more than doubles adjusted EBITDA margin
LEO Pharma delivers 10% revenue growth in 2025 and more than doubles adjusted EBITDA margin Ballerup, Denmark, 18 February, 2026 – In 2025, LEO Pharma delivered a third consecutive year of double‑digit revenue…
-
LEO Pharma to present at the 44th annual J.P. Morgan Healthcare Conference
LEO Pharma to present at the 44th annual J.P. Morgan Healthcare Conference Ballerup, Denmark, January 7, 2026 – LEO Pharma, a global leader in medical dermatology, announced today that…
-
LEO Pharma appoints Marika Murto to lead Global Product Strategy
LEO Pharma appoints Marika Murto to lead Global Product Strategy Ballerup, Denmark, December 16, 2025 – LEO Pharma, a global leader in medical dermatology, announces the appointment of Marika…
-
LEO Pharma delivers 8% revenue growth at CER in 9M 2025 and updates full-year outlook
LEO Pharma delivers 8% revenue growth at CER in 9M 2025 and updates full-year outlook Ballerup, Denmark, 6 November, 2025 – In the first nine months of 2025, LEO…
Media Inquiries
Head of Media
+4530502014
JEILK@leo-pharma.com
SVP, Head of Corporate Communications
+4529407016
ANMRN@leo-pharma.com
Media Manager
+4553748849
CHBUN@leo-pharma.com
About LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com
Our press releases are intended for the media
To comply with applicable regulation, product-related press releases are removed from our website within three weeks of publication. They are available upon request. For updated information about clinical trials, please visit https://clinicaltrials.gov/.